LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.79
−0.26%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.39
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.30
- EPS estimate
- -$0.38
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -14.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $8.00
- PT range
- $5.00 – $11
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.38 | -$0.30 | Beat 21.35% | — |
| May 14, 2026 | -$0.53 | -$0.31 | Beat 41.51% | — |
| Mar 19, 2026 | -$0.44 | -$0.73 | Miss -65.91% | — |
| Nov 5, 2025 | -$0.39 | -$0.61 | Miss -56.41% | — |
| Aug 14, 2025 | -$0.47 | -$0.41 | Beat 12.77% | — |
| Apr 30, 2025 | -$0.42 | -$0.46 | Miss -9.52% | — |
| Mar 24, 2025 | -$0.29 | -$0.45 | Miss -55.17% | $241.0K |
| Oct 30, 2024 | -$0.37 | -$0.24 | Beat 35.14% | — |
| May 9, 2024 | -$0.24 | -$0.27 | Miss -12.50% | — |
| Mar 14, 2024 | -$0.25 | -$0.30 | Miss -20.00% | — |
| Nov 14, 2023 | -$0.23 | -$0.21 | Beat 8.70% | — |
| Aug 10, 2023 | -$0.21 | -$0.19 | Beat 9.52% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026